Literature DB >> 2620671

Serum levels of ciprofloxacin after single oral doses in patients with septicemia.

M D'Espine1, F Bellido, J C Pechère, R Auckenthaler, P Rohner, D Lew, B Hirschel.   

Abstract

Ciprofloxacin serum levels were measured after administration of the drug to 36 patients with septicemia (at least one positive blood culture) who were able to take oral medication. Patients were randomly allocated to receive ciprofloxacin 500 mg p.o. (n = 21) or 200 mg i.v. over 30 min (n = 15). A first dose was administered 18-30 h after the last positive blood culture (day 1), and a second dose four days later (day 5) in some patients. In addition to ciprofloxacin, standard antibiotics were administered. Organisms isolated were Escherichia coli (15), other gram-negative bacteria (6), Streptococcus pneumoniae (7), Staphylococcus aureus (2), and other gram-positive bacteria (6). None of the patients vomited. Ciprofloxacin serum concentrations 1 h after oral administration were in the range 0.09-2.32 mg/l, and 2 h after administration in the range 0.5-7.27 mg/l. The average terminal half-life was 8.6 h. In individual patients serum concentrations and area-under-the-curve values were compared. Poor correlation was found between values measured on day 1 and day 5 after oral administration, whereas the correlation was excellent after i.v. administration. Serum levels 2 h after oral administration were 30-900 times the MICs for the gram-negative organisms, but were in the range of the MICs for the gram-positive organisms in some cases. In conclusion, ciprofloxacin serum levels are difficult to predict in septicemia patients after oral administration, but probably suffice to treat infections caused by gram-negative organisms.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2620671     DOI: 10.1007/bf01975162

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  12 in total

1.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

2.  Comparative evaluation of the BCB Roche and Oxoid Signal blood culture systems.

Authors:  P Rohner; R Auckenthaler
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-02       Impact factor: 3.267

3.  Pharmacokinetics of oral ciprofloxacin, 100 mg single dose, in volunteers and elderly patients.

Authors:  A P Ball; C Fox; M E Ball; I R Brown; J V Willis
Journal:  J Antimicrob Chemother       Date:  1986-05       Impact factor: 5.790

4.  Pharmacokinetics of ciprofloxacin in elderly subjects.

Authors:  M LeBel; G Barbeau; M G Bergeron; D Roy; F Vallée
Journal:  Pharmacotherapy       Date:  1986 Mar-Apr       Impact factor: 4.705

5.  Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis.

Authors:  H R Stutman; I Shalit; M I Marks; R Greenwood; S A Chartrand; B C Hilman
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

6.  Pharmacokinetics of ciprofloxacin in acutely ill and convalescent elderly patients.

Authors:  D R Guay; W M Awni; P K Peterson; S Obaid; R Breitenbucher; G R Matzke
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

7.  Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers.

Authors:  W Wingender; K H Graefe; W Gau; D Förster; D Beermann; P Schacht
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

Review 8.  Clinical pharmacokinetics of the newer antibacterial 4-quinolones.

Authors:  M Neuman
Journal:  Clin Pharmacokinet       Date:  1988-02       Impact factor: 6.447

9.  Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses.

Authors:  T Bergan; S B Thorsteinsson; R Solberg; L Bjornskau; I M Kolstad; S Johnsen
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

10.  In-vitro activity of newer quinolones against aerobic bacteria.

Authors:  R Auckenthaler; M Michéa-Hamzehpour; J C Pechère
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

View more
  4 in total

1.  Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients.

Authors:  J Schrenzel; F Cerruti; M Herrmann; T Leemann; E Weidekamm; R Portmann; B Hirschel; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

Review 2.  Pharmacokinetics of quinolones: newer aspects.

Authors:  J S Wolfson; D C Hooper
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

3.  Synergistic effect of antibiotic combinations on Staphylococcus aureus biofilms and their persister cell populations.

Authors:  Ekta Kamble; Purva Sanghvi; Karishma Pardesi
Journal:  Biofilm       Date:  2022-02-02

4.  Metrics of Antifungal Effects of Ciprofloxacin on Aspergillus fumigatus Planktonic Growth and Biofilm Metabolism; Effects of Iron and Siderophores.

Authors:  Gabriele Sass; Lynn Scherpe; Marife Martinez; Julianne J Marsh; David A Stevens
Journal:  J Fungi (Basel)       Date:  2022-02-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.